Biomet Buyout - News

Runway Angels
The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.
Smartphone Guide
Here's a need-to-know guide to nine devices, based on features, price, network and platform.
Wines for the Holidays
Not quite sure what wine to pair with Turkey or Creme Brulee? Our experts do.

FEATURED QUIZZES

How Well Do You Know Your Bird?
Let's talk turkey. Test your turkey knowledge and perhaps pick up a bit of trivia to trot out at your holiday meal.
A Healthier & Wealthier You
Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.
The Billionaire BFF's
Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

SPECIAL REPORTS

Winterizing Your Portfolio
If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.
Investor's Guide to Real Estate
Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.
Alternative Investing
Stocks and bonds? Sure. But it's a big world out there for investors.

CNBC ON DIGG

Biomet Accepts $10.9 Billion Buyout Offer

Topics:Mergers & Acquisitions | Private Equity

Sectors:Health Care

By: AP | 18 Dec 2006 | 04:34 PM ET

Text Size

Biomet, a maker of hip and knee replacement products, [BMET Loading... () ] has agreed to be acquired by a private equity consortium for about $10.9 billion in cash.

The buyers include Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts and the Texas Pacific Group, along with one of Biomet's founders, Dane A. Miller.

Shareholders are being offered $44 a share, a 27% premium to Biomet's price on April 3, the trading day before news surfaced that the company was a takeover target. Biomet started looking for a buyer with the help of Morgan Stanley on April 6.

The buyers said they will use a combination of their own cash and borrowed funds from Bank of America and Goldman Sachs to finance the takeover.

The board of Biomet voted in favor of the transaction, which is subject to shareholder approval and antitrust clearance.

Biomet said the transaction is expected to be complete by Oct. 31, and the company's stock will be delisted from the Nasdaq Stock Market.

Last week, UBS analyst Kristen M. Stewart wrote in a report that a private equity buyout wouldn't be justified at more than $43 per share.

Separately, Biomet said it is delaying the release of its fiscal second-quarter financial results because of a continuing review of its stock options practices since 1996. But the company did disclose that its unaudited sales for the quarter were $520.3 million.